Skip to content

News

OCRF Research Provides Further Evidence that Ovarian Cancer...

OCRF Research Provides Further Evidence that Ovarian Cancer Originates in Fallopian Tube

02/16/2012   Work funded by Ovarian Cancer Research Fund has shown that the high-grade serous ovarian cancer arises in the fallopian tube of mice that lack two specific genes. The report appeared online this week in the journal Proceedings of the National Academy of Sciences. Little is known about how ovarian cancer starts and spreads. Recent … Continued

Study Finds BRCA Mutation Boosts Ovarian Cancer Survival

Study Finds BRCA Mutation Boosts Ovarian Cancer Survival

01/27/2012   A large, multicenter study shows that women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes have better survival rates than women who do not have such mutations. The study is also the first to provide strong evidence that ovarian cancer prognosis is better for women with BRCA2 mutations than … Continued

New Study Evaluates Usefulness of New Symptom Indices

New Study Evaluates Usefulness of New Symptom Indices

01/24/2012 The use of symptom indices to identify patients with symptoms associated with ovarian cancer who may need further screening is increasing in both the UK and the US in an attempt to promote earlier diagnosis, but these indices may need to be reassessed in order to help better detect cancer, according to a study … Continued

OCRF Researchers Discover Genomic Complexity and AKT Depend...

OCRF Researchers Discover Genomic Complexity and AKT Dependence in Serous Ovarian Cancer

01/20/2012                Dr. Doug Levine and Dr. Carol Aghajanian, both recipients of OCRF grants, were part of a project recently published in Cancer Discovery that studied AKT inhibition in ovarian cancer cell lines with various mechanisms of AKT pathway activation. Researchers found that some cell lines were responsive to AKT inhibitors, but depended greatly on other, co-existent, … Continued

Meet OCRF’s 2012 Grantees

Meet OCRF’s 2012 Grantees

OCRF has awarded $5.4 million in grants for ovarian cancer research this year. After receiving over 100 applications – the highest number in its history – OCRF and its prestigious Scientific Advisory Committee endeavored first and foremost to fund the best science. The Committee evaluated each proposal through intensive peer review, and selected a sound … Continued

Ovarian Cancer Research Fund Awards $5.4 Million in 2012 Re...

Ovarian Cancer Research Fund Awards $5.4 Million in 2012 Research Grants

OCRF receives record number of grant applications; continues to fund the best science New York, NY January 3, 2012— Ovarian Cancer Research Fund (OCRF) has awarded $5.4 million in grants for ovarian cancer research this year. After receiving over 100 applications – the highest number in its history – OCRF and its prestigious Scientific Advisory … Continued

New Genetic Mutation Increases Risk of Ovarian Cancer

New Genetic Mutation Increases Risk of Ovarian Cancer

08/17/2011Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer.  This major finding was published online in the journal Nature Genetics on August 7th. Much like the BRCA1 and BRCA2 mutations, which were discovered in the 1990s and which also increase a woman’s risk for ovarian cancer, … Continued

Researchers Create Genetic "Map" of Ovarian Cancer

Researchers Create Genetic "Map" of Ovarian Cancer

In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a genetic “map” of ovarian cancer.  This important work, which is the largest study of any tumor type to date, will help researchers better understand the … Continued

2011 SGO News: GI Risk Clarified for Bevacizumab

2011 SGO News: GI Risk Clarified for Bevacizumab

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.

2011 SGO News: Genetic Test May Spot Increased Risk for In...

2011 SGO News: Genetic Test May Spot Increased Risk for Inherited Ovarian Cancer

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.